Aviran Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 3.50 Cr
- Paid Up Capital ₹ 3.50 Cr
- Company Age 3 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.95 Cr
- Revenue Growth %
- Net Worth 312.24%
- Total Assets 856.72%
About Aviran Pharmachem
Aviran Pharmachem Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 February 2021 (Three years and 11 months 23 days old ). Its registered office is in Mahesana, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.50 Cr and a paid-up capital of Rs 3.50 Cr.
The company currently has active open charges totaling ₹9.95 Cr.
Amitkumar Patel, Kirankumar Patel, and Vipulkumar Patel serve as directors at the Company.
Company Details
- Location
Mahesana, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24233GJ2021PTC120025
- Company No.
120025
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Feb 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Aviran Pharmachem?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amitkumar Patel  | Director | 05-Feb-2021 | Current |
| Kirankumar Patel | Director | 05-Feb-2021 | Current |
| Vipulkumar Patel | Director | 05-Feb-2021 | Current |
Financial Performance of Aviran Pharmachem.
Aviran Pharmachem Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth Soared by an impressive increase of 312.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Aviran Pharmachem?
Unlock access to Aviran Pharmachem's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹9.95 Cr
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 9.95 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Jul 2022 | State Bank Of India | ₹9.95 Cr | Open |
How Many Employees Work at Aviran Pharmachem?
Aviran Pharmachem has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aviran Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aviran Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.